FMO3 and atherosclerosis: Previous studies have shown that the LXR-IDOL-LDLR feedback [26], the SREBP2/PCSK9 pathway [27], and liver FMO3 expression [28] mediate the liver lipid, cholesterol, and TMAO metabolism levels in atherosclerosis.